JAMP-SIMVASTATIN TABLET

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

SIMVASTATIN

Saadav alates:

JAMP PHARMA CORPORATION

ATC kood:

C10AA01

INN (Rahvusvaheline Nimetus):

SIMVASTATIN

Annus:

20MG

Ravimvorm:

TABLET

Koostis:

SIMVASTATIN 20MG

Manustamisviis:

ORAL

Ühikuid pakis:

21/30/100/500/1000

Retsepti tüüp:

Prescription

Terapeutiline ala:

HMG-COA REDUCTASE INHIBITORS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0122415003; AHFS:

Volitamisolek:

CANCELLED POST MARKET

Loa andmise kuupäev:

2013-07-08

Toote omadused

_Jamp-Simvastatin (simvastatin) tablets_
_Page 1 of 47_
PRODUCT MONOGRAPH
PR
JAMP-SIMVASTATIN
Simvastatin Tablets, USP
5 mg, 10 mg, 20 mg, 40 mg and 80 mg
Lipid Metabolism Regulator
JAMP Pharma Corporation
Date of Revision:
1310 rue Nobel
June 14, 2019
Boucherville, Québec,
Canada
J4B 5H3
Submission Control No: 227575
_Jamp-Simvastatin (simvastatin) tablets_
_Page 2 of 47_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................. 3
SUMMARY PRODUCT INFORMATION
............................................................................
3
INDICATIONS AND CLINICAL USE
...............................................................................
3
CONTRAINDICATIONS
........................................................................................................
5
WARNINGS AND
PRECAUTIONS......................................................................................
5
ADVERSE REACTIONS
......................................................................................................
12
DRUG INTERACTIONS
......................................................................................................
15
DOSAGE AND ADMINISTRATION
..................................................................................
19
OVERDOSAGE
.....................................................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
................................................................ 21
STORAGE AND STABILITY
..............................................................................................
22
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................ 22
PART II: SCIENTIFIC INFORMATION
....................................................................................
23
PHARMACEUTICAL INFORMATION
.............................................................................
23
CLINICAL TRIALS
............................................